Loading...
Docoh

Intra-Cellular Therapies (ITCI)

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases.

ITCI stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

9 Aug 22
29 Sep 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 78.64M 78.64M 78.64M 78.64M 78.64M 78.64M
Cash burn (monthly) 17.35M 3.65M 29.31M 26.99M 31.6M 27.51M
Cash used (since last report) 51.75M 10.88M 87.4M 80.49M 94.22M 82.03M
Cash remaining 26.89M 67.75M -8.76M -1.86M -15.59M -3.39M
Runway (months of cash) 1.5 18.6 -0.3 -0.1 -0.5 -0.1

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
21 Sep 22 Lawrence J. Hineline Common Stock Sell Dispose S No Yes 45.39 33,303 1.51M 0
21 Sep 22 Lawrence J. Hineline Common Stock Sell Dispose S No Yes 45.88 31,861 1.46M 33,303
21 Sep 22 Lawrence J. Hineline Common Stock Option exercise Acquire M No No 15.47 65,164 1.01M 65,164
21 Sep 22 Lawrence J. Hineline Stock Option Common Stock Option exercise Dispose M No No 15.47 65,164 1.01M 0
11 Aug 22 Marcus Joel S Common Stock Sell Dispose S No No 59.22 10,000 592.2K 44,233
11 Aug 22 Van Nostrand Robert L Common Stock Sell Dispose S No No 56.8 1,500 85.2K 9,043
11 Aug 22 Van Nostrand Robert L Common Stock Sell Dispose S No No 57.15 28,500 1.63M 10,543
11 Aug 22 Van Nostrand Robert L Common Stock Option exercise Acquire M No No 13.05 10,000 130.5K 39,043
11 Aug 22 Van Nostrand Robert L Common Stock Option exercise Acquire M No No 12.45 20,000 249K 29,043
11 Aug 22 Van Nostrand Robert L Stock Option Common Stock Option exercise Dispose M No No 13.05 10,000 130.5K 10,000
13F holders Current Prev Q Change
Total holders 260 235 +10.6%
Opened positions 46 65 -29.2%
Closed positions 21 37 -43.2%
Increased positions 92 88 +4.5%
Reduced positions 88 62 +41.9%
13F shares Current Prev Q Change
Total value 4.77B 5.01B -5.0%
Total shares 83.93M 83.41M +0.6%
Total puts 287.2K 241.1K +19.1%
Total calls 327.8K 437.4K -25.1%
Total put/call ratio 0.9 0.6 +58.9%
Largest owners Shares Value Change
FMR 10.33M $589.81M -5.7%
Vanguard 8.08M $461.22M +3.7%
BLK Blackrock 7.05M $402.32M +8.9%
Wasatch Advisors 5.39M $307.72M -27.9%
Wellington Management 4.46M $254.77M +9.9%
BBBOF BB Biotech 3.54M $112.52M 0.0%
BLVGF Bellevue 3.35M $191.18M -2.3%
Alliancebernstein 2.11M $120.59M +2130.6%
STT State Street 1.92M $109.58M +7.1%
Lord, Abbett & Co. 1.85M $105.65M -6.6%
Largest transactions Shares Bought/sold Change
Marshall Wace 0 -2.52M EXIT
Wasatch Advisors 5.39M -2.09M -27.9%
Alliancebernstein 2.11M +2.02M +2130.6%
Holocene Advisors 1.63M +904.68K +125.2%
Avidity Partners Management 775.5K +775.5K NEW
FMR 10.33M -621.65K -5.7%
BLK Blackrock 7.05M +577.94K +8.9%
Brandywine Global Investment Management 31.53K -537.28K -94.5%
Wellington Management 4.46M +402.2K +9.9%
Pictet Asset Management 1.11M -371.91K -25.0%

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: alleging, anda, brain, breach, complaint, Court, defendant, duty, emergency, enrichment, federal, fiduciary, infected, lawsuit, merit, neuroimaging, nominal, occupancy, play, purported, redeployment, role, serving, shelter, strain, Supreme, unjust, visit
Removed: abatement, abroad, acceptability, accrued, administered, advanced, announced, arrangement, assessment, bythe, comparison, cycle, defer, domestic, feasible, February, foreign, fourth, furthest, inadequate, inform, intended, intention, issue, line, local, locality, Maryland, noted, postpone, postponed, prioritized, put, rating, resulting, resuming, resumption, routine, safely, safest, subcutaneously, subsequently, substantially, surveillance, temporarily, therapeutic, Towson, trajectory, user, vivarium

Patents

Utility
Substituted heterocycle fused gamma-carbolines synthesis
27 Sep 22
The present invention provides improved methods for the preparation of substituted heterocycle fused gamma-carbolines, intermediates useful in producing them and methods for producing such intermediates and such heterocycle fused gamma-carbolines.
Utility
Organic Compounds
22 Sep 22
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the μ-opioid receptor.
Utility
Salts and crystals
13 Sep 22
The disclosure provides new, stable, pharmaceutically acceptable hydrochloride salt forms of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.
Utility
Organic Compounds
8 Sep 22
The disclosure relates to methods of administering comprising administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and/or prophylaxis of renal disorders, such as chronic kidney disease.
Utility
Novel Salts and Crystals
8 Sep 22
The disclosure provides a new, stable, pharmaceutically acceptable bis-tosylate salt form of 1-(4-fluoro-phenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9,10, 10a-hexahydro-1H,7H-pyrido [3′,4′:4,5]pyrrolo [1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.